Global

CN EN
  1. HOME
  2. ABOUT US
    About Laekna Core Management Team Board of Directors Milestones Scientific Advisory Board Core Investors Honors & Awards
  3. R&D
    R&D Therapeutic Areas Candidates Pipeline Clinical Trials
  4. PARTNERSHIPS
    Strategic Partners Business Development Holistic Approach BD Contact
  5. INVESTORS
    Corporate Governance Financial Results Announcements and Circulars IR Calendar Listing Documents
  6. NEWS
    Press Releases Media Coverage
  7. CAREERS
    Global Team Career Development Jobs My Laekna
  8. CONTACT US
    Contact Us Leave Message
  9. RSS Feeds
NEWS
PRESS CENTER

Scroll down to see more

Index > R&D> Clinical Trials> More

Solid Tumor
NSCLC
Cervical Cancer
Endometrial Cancer
Esophageal Cancer
Gastric and Gastroesophageal Junction Adenocarcinoma

2023-03-22

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Last:none
Next:Solid Tumor
TNBC Triple-Negative Breast Cancer
Back
Media contact

e-mail:communication@laekna.com

Contact us
Recommendation
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin

  1. HOME
  2. ABOUT US
  3. R&D
  4. PARTNERSHIPS
  5. INVESTORS
  6. NEWS
  7. CAREERS
  8. CONTACT US

Copyright © Laekna Therapeutics, All Rights Reserved.  沪ICP备17047795号 Privacy Policy

Follow us on Linkedin

Follow us on Wechat